Titov Sergei E, Kozorezova Evgeniya S, Demenkov Pavel S, Veryaskina Yulia A, Kuznetsova Irina V, Vorobyev Sergey L, Chernikov Roman A, Sleptsov Ilya V, Timofeeva Nataliya I, Ivanov Mikhail K
Department of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, SB RAS, 630090 Novosibirsk, Russia.
AO Vector-Best, 630117 Novosibirsk, Russia.
Cancers (Basel). 2021 Jan 11;13(2):237. doi: 10.3390/cancers13020237.
In previous studies, we described a method for detecting and typing malignant tumors of the thyroid gland in fine-needle aspiration biopsy samples via analysis of a molecular marker panel (normalized mRNA level; normalized microRNA-146b, -221, and -375 levels; mitochondrial-to-nuclear DNA ratio; and mutation) in cytological preparations by quantitative PCR. In the present study, we aimed to estimate the specificity of the typing of different thyroid tumors by the proposed method. Fine-needle aspiration cytological preparations from 278 patients were used. The histological diagnosis was known for each sample. The positive and negative predictive values of the method assessed in this study were, respectively, 100% and 98% for papillary thyroid carcinoma ( = 63), 100% and 100% for medullary thyroid carcinoma ( = 19), 43.5% and 98% for follicular carcinoma ( = 15), and 86% and 100% for Hürthle cell carcinoma ( = 6). Thus, we demonstrate that the diagnostic panel, including the analysis of microRNA expression, mRNA expression, the mutation, and the mitochondrial-to-nuclear DNA ratio, allows the highly accurate identification of papillary thyroid carcinoma, medullary thyroid carcinoma, and Hürthle cell carcinoma but not malignant follicular tumors (positive predictive value was below 50%).
在先前的研究中，我们描述了一种通过定量聚合酶链反应分析细针穿刺活检样本中分子标志物组（标准化mRNA水平、标准化微小RNA-146b、-221和-375水平、线粒体与核DNA比率以及突变）来检测甲状腺恶性肿瘤并进行分型的方法。在本研究中，我们旨在评估所提出的方法对不同甲状腺肿瘤分型的特异性。使用了278例患者的细针穿刺细胞学样本。每个样本的组织学诊断均已知。本研究中评估的该方法对甲状腺乳头状癌（n = 63）的阳性和阴性预测值分别为100%和98%，对甲状腺髓样癌（n = 19）为100%和100%，对滤泡癌（n = 15）为43.5%和98%，对许特莱细胞癌（n = 6）为86%和100%。因此，我们证明，包括分析微小RNA表达、mRNA表达、突变以及线粒体与核DNA比率的诊断组能够高度准确地识别甲状腺乳头状癌、甲状腺髓样癌和许特莱细胞癌，但不能识别恶性滤泡性肿瘤（阳性预测值低于50%）。
